Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress

thestreet2021-06-17

Shares of Clearside Biomedical(CLSD) jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study. Wedbush ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Ruzzer
2021-06-18
Ruzzer
Good
Haohao2324
2021-06-18
Haohao2324
Like n comment
- Huathk:
  Gd
Shunnie
2021-06-18
Shunnie
Ooo
Sky0501
2021-06-18
Sky0501
?
梁娜娜本人
2021-06-18
梁娜娜本人
Oh
Samsonn
2021-06-18
Samsonn
1-0

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179547045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-17 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179547045","market":"us","top_or_hot":-1,"title":"Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress","media":"thestreet","content":"<div>\n<p>Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush ...</p>\n\n<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush ...</p>\n\n<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLSD","symbol_name":"Clearside Biomedical Inc.","start_time":0,"source_url":"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade","article_id":"1179547045","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179547045","pubTimestamp":1623941450,"sourceInfo":null,"weMediaInfo":null,"summary":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their pri","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLSD":"Clearside Biomedical Inc."},"translate_title":"空地跳跃；Wedbush Triples靶点眼用药物试验进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLSD":0.9},"content_text":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.\n\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.\nShares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.\nClearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.\nEarlier this week the company reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.\nClearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.\nThe company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.\nEarlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":166804781,"gmtCreate":1623999927943,"gmtModify":1703826184706,"author":{"id":"3564564201334764","authorId":"3564564201334764","name":"Ruzzer","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166804781","repostId":1179547045,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168608883,"gmtCreate":1623973075742,"gmtModify":1703824917544,"author":{"id":"3572824646640760","authorId":"3572824646640760","name":"Haohao2324","avatar":"https://static.tigerbbs.com/5741ee0bde82c7782d814be80e181a3e","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/168608883","repostId":1179547045,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4853332,"gmtCreate":1623977467780,"gmtModify":1663229222346,"authorId":3573472992263411,"author":{"id":3573472992263411,"authorId":3573472992263411,"name":"Huathk","avatar":"https://static.tigerbbs.com/43c7168c646d9ea6805194ed0003f1cc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":168608883,"type":1,"supId":0,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"}],"langContent":"EN"},{"id":168891866,"gmtCreate":1623970108855,"gmtModify":1703824792734,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ooo","listText":"Ooo","text":"Ooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168891866","repostId":1179547045,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168165922,"gmtCreate":1623966598566,"gmtModify":1703824714031,"author":{"id":"3573257474509177","authorId":"3573257474509177","name":"Sky0501","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168165922","repostId":1179547045,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168118643,"gmtCreate":1623964459582,"gmtModify":1703824685238,"author":{"id":"3573131687370671","authorId":"3573131687370671","name":"梁娜娜本人","avatar":"https://community-static.tradeup.com/news/0621ca24acbe93afcdca93761ac78994","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168118643","repostId":1179547045,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168323293,"gmtCreate":1623952136312,"gmtModify":1703824590310,"author":{"id":"3583055835109040","authorId":"3583055835109040","name":"Samsonn","avatar":"https://static.tigerbbs.com/83d50aad662460d0d773f3a4b82018e2","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":1},"htmlText":"1-0","listText":"1-0","text":"1-0","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168323293","repostId":1179547045,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":67,"commentSize":37,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179547045"}